GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bluejay Diagnostics Inc (NAS:BJDX) » Definitions » Cash-to-Debt

Bluejay Diagnostics (Bluejay Diagnostics) Cash-to-Debt : 6.26 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Bluejay Diagnostics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Bluejay Diagnostics's cash to debt ratio for the quarter that ended in Dec. 2023 was 6.26.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Bluejay Diagnostics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Bluejay Diagnostics's Cash-to-Debt or its related term are showing as below:

BJDX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09   Med: 6.26   Max: No Debt
Current: 6.26

During the past 5 years, Bluejay Diagnostics's highest Cash to Debt Ratio was No Debt. The lowest was 0.09. And the median was 6.26.

BJDX's Cash-to-Debt is ranked better than
67.83% of 861 companies
in the Medical Devices & Instruments industry
Industry Median: 1.87 vs BJDX: 6.26

Bluejay Diagnostics Cash-to-Debt Historical Data

The historical data trend for Bluejay Diagnostics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Bluejay Diagnostics Cash-to-Debt Chart

Bluejay Diagnostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
0.09 0.86 No Debt 20.52 6.26

Bluejay Diagnostics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.52 14.78 12.03 13.05 6.26

Competitive Comparison of Bluejay Diagnostics's Cash-to-Debt

For the Medical Devices subindustry, Bluejay Diagnostics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bluejay Diagnostics's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bluejay Diagnostics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Bluejay Diagnostics's Cash-to-Debt falls into.



Bluejay Diagnostics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Bluejay Diagnostics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Bluejay Diagnostics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bluejay Diagnostics  (NAS:BJDX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Bluejay Diagnostics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Bluejay Diagnostics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Bluejay Diagnostics (Bluejay Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
360 Massachusetts Avenue, Suite 203, Acton, MA, USA, 01720
Bluejay Diagnostics Inc is a medical diagnostics company. It is engaged in developing, manufacturing, and marketing of clinical diagnostic products that improve the quality of medical diagnoses. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings. The company is a provider of rapid tests for infectious, inflammatory, and metabolic diseases by the Symphony platform.
Executives
Svetlana Dey director, 10 percent owner 360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Indranil Dey director, 10 percent owner, officer: Chief Technology Officer 360 MASSACHUSETTS AVENUW, SUITE 203, ACTON MA 0170
Frances P Scally officer: CFO 66 MELANIE LANE, SYOSSET NY 11791
Jason Cook officer: Chief Technology Officer 360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Kenneth R Fisher officer: Chief Financial Officer 67 PROSPECT STREET, PEABODY MA 01960
Douglas Clark Wurth director, 10 percent owner 4265 SAN FELIPE, SUITE 603, HOUSTON TX 77027
Gordon Winston Kinder officer: Chief Financial Officer 360 MASSACHUSETTS AVENUE, SUITE 203, ACTON MA 01720
Gary G Gemignani director C/O IASO PHARMA INC., 12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Fred S Zeidman director 109 NORTH POST OAK LANE, SUITE 422, HOUSTON TX 77024
Donald R Chase director 39 TIMBER RIDGE RD., WEST SPRINGFIELD MA 01089